The meeting provided a bench-to-bedside overview of the targeting of interleukin-17 (IL-17) for the treatment of psoriasis. Prof Kristian Reich described state-of-the-art research into the IL-17 pathway in psoriasis, and how this pathway is being targeted by a new generation of biologics. An overview of the most up-to-date Phase II and Phase III data available for agents targeting the IL-17 pathway, along with a discussion of the link between clinical efficacy and quality of life (QoL) outcomes, was presented by Prof Kenneth Gordon. Finally, Prof Christopher Griffiths discussed how the superior efficacy of the new anti-IL-17 biologics enables physicians to aim higher in terms of achievable clinical benefits for patients, reaching beyond the current accepted clinical standard of PASI 75 – a 75% reduction in symptoms on the Psoriasis Area Severity Index (PASI) – and to have a greater impact on patient QoL.
Please view the full content in the pdf above.